Daily Cardiology Research Analysis
Analyzed 106 papers and selected 3 impactful papers.
Summary
Analyzed 106 papers and selected 3 impactful articles.
Selected Articles
1. Enhancing KLF15 activity in cardiomyocytes: a novel approach to prevent pathological reprogramming and fibrosis via nuclease-deficient dCas9VPR.
Using CRISPRa to boost KLF15 activity in cardiomyocytes suppressed fetal gene reprogramming, restored metabolic homeostasis, and reduced fibrosis via AZGP1-mediated cardiomyocyte–fibroblast crosstalk. The study positions KLF15 as a TGF-β–regulated node and delivers a compact AAV-CRISPRa platform for endogenous transcriptional augmentation.
Impact: This work pioneers transcription-factor restoration therapy for non-genetic heart failure using CRISPRa, linking a defined TF (KLF15) to anti-fibrotic signaling and providing a translational AAV toolkit.
Clinical Implications: While preclinical, the approach suggests a gene-regulatory therapy to blunt pathological remodeling and fibrosis in heart failure and provides a vector platform potentially adaptable to additional cardiac targets.
Key Findings
- Single-cell network analysis identified decreased KLF15 activity as a hallmark of pathological cardiomyocytes.
- Cardiomyocyte-targeted CRISPRa restored KLF15, suppressing fetal reprogramming and normalizing metabolism under stress.
- KLF15-dependent AZGP1 mediated an anti-fibrotic, cell-nonautonomous effect via cardiomyocyte–fibroblast crosstalk.
- KLF15 acts downstream of canonical TGF-β signaling; a compact AAV-CRISPRa system enabled endogenous TF augmentation.
Methodological Strengths
- Integrative multi-modal approach: single-cell network analysis, in vivo stress models, and human cardiomyocytes.
- Development and validation of a compact AAV-CRISPRa platform enabling endogenous transcriptional activation.
Limitations
- Preclinical study without human in vivo efficacy or long-term safety data.
- Potential off-target transcriptional effects and immunogenicity of AAV-CRISPRa require rigorous evaluation.
Future Directions: Assess long-term safety/efficacy and off-target profiles in large-animal models, optimize cardiac-specific delivery, and explore KLF15-CRISPRa combinations with anti-fibrotic pharmacotherapies.
Transcriptional activity perturbation holds promise for selectively modulating harmful transcriptional networks, but its therapeutic potential remains largely unexplored. We employed a network-based analysis of single-cell heart transcriptomes to identify transcription factor activities linked to pathological cardiomyocytes in vivo. This analysis revealed that transcriptional activity of Krüppel-like factor 15 (KLF15) exhibited the most significant change in pathological cardiomyocytes, characterized by less effective repression of disease-associated genes in stressed hearts, which correlated with reduced KLF15 expression. To restore KLF15 activity, we utilized CRISPR/nuclease-dead (d)Cas9-based transcriptional enhancement (CRISPRa) in cardiomyocytes, which effectively abolished fetal reprogramming by simultaneously suppressing pathological gene expression and restoring metabolic homeostasis under sustained stress conditions. Furthermore, we identified a novel cell-nonautonomous anti-fibrotic effect mediated by cardiomyocyte-fibroblast crosstalk, and revealed the contribution of KLF15-dependent Alpha-2-glycoprotein 1, zinc-binding (AZGP1) regulation in this process. We also elucidated the upstream mechanisms of KLF15 regulation, highlighting its role as a cell-specific downstream target of the broad TGF-β canonical signaling pathway, along with its downstream-dependent mechanisms in human cardiomyocytes. Finally, to enhance the therapeutic potential of this approach, we engineered and validated an adeno-associated viral (AAV) vector with a small CRISPRa system for endogenous regulation in human cardiomyocytes suitable for clinical applications. Overall, we elucidated a regulatory circuit involving TGF-β, KLF15, and AZGP1, which coordinates critical pathological responses through cellular crosstalk between cardiomyocytes and fibroblasts. Importantly, we demonstrated the efficacy of CRISPRa as an epigenetic intervention restoring a critical transcriptional function disrupted in non-genetic heart failure. This approach provides a promising blueprint for future adaptation targeting additional non-hereditary pathologies.
2. Gut Microbiota Dysbiosis Promotes CKD-associated Atrial Fibrillation Through Activation of the NLRP3 Inflammasome.
In adenine-induced CKD rats, gut dysbiosis elevated indoxyl sulfate, disrupted gut barrier function, increased circulating LPS, and activated atrial TLR4–NLRP3 inflammasome signaling, increasing AF susceptibility. AF risk transferred via FMT and was mitigated by AST-120, gut barrier protectants, and Lactobacillus gasseri.
Impact: Identifies a microbiota–IS–LPS–TLR4–NLRP3 axis as a causal driver of CKD-associated AF with multiple modifiable intervention points, opening microbiome-based prevention strategies.
Clinical Implications: Suggests testable interventions (AST-120, gut barrier protectants, probiotic supplementation) to reduce AF risk in CKD; supports biomarker-guided strategies (IS, LPS) and atrial innate immune targeting.
Key Findings
- CKD rats developed gut dysbiosis and heightened AF susceptibility transferable to healthy rats via FMT.
- Mechanism: elevated indoxyl sulfate impaired gut barrier, increased circulating LPS, activated atrial TLR4–NLRP3 inflammasome.
- Interventions (AST-120, gut barrier protectants, Lactobacillus gasseri) reduced IS/LPS signaling and mitigated AF susceptibility.
Methodological Strengths
- Causality supported by fecal microbiota transplantation and mono-colonization experiments.
- Convergent pharmacologic/nutritional interventions targeting distinct nodes (IS scavenging, barrier protection, probiotic).
Limitations
- Preclinical rat model; absence of human interventional validation.
- Adenine diet CKD model may not recapitulate all human CKD phenotypes; sample sizes per arm not detailed.
Future Directions: Validate IS–LPS–NLRP3 signatures and microbiota interventions in CKD patients at AF risk; test atrial innate immune modulation (TLR4/NLRP3) and personalized probiotic strategies.
BACKGROUND: Chronic kidney disease (CKD) significantly increases the risk of atrial fibrillation (AF). Although alterations in the gut microbiota have been linked to CKD progression, its exact involvement in CKD-associated AF remians unclear. We amis to investigate the role of gut microbiota in the development of CKD-associated AF, and to uncover potential mechanisms that could serve as effective targets for prevention and treatment. METHODS AND RESULTS: A rat model of CKD was induced by an adenine-enriched diet. 16S rRNA sequencing and fecal microbiota transplantation (FMT) were utilized to study the involvement of gut microbiota. AST-120, gut barrier protectants and mono-colonization experiments were performed to investigate potential mechanism. CKD rats exhibited gut microbiota dysbiosis and a significantly increased susceptibility to AF. FMT from CKD rats transferred this heightened AF susceptibility to healthy recipient rats, linked to the activation of the NLRP3 inflammasome. Mechanistically, gut dysbiosis in CKD patients leads to elevated IS levels, causing gut barrier dysfunction and increased circulating lipopolysaccharide (LPS). Elevated LPS activates atrial TLR4 receptors, triggering NLRP3 inflammasome activation, which contributes to AF pathogenesis. Treatment with the IS scavenger AST-120 or gut barrier protectants successfully prevented CKD-associated AF. Furthermore, supplementation with Lactobacillus gasseri reduced circulating IS levels and mitigated AF susceptibility in CKD rats. CONCLUSION: This study demonstrates that gut dysbiosis-driven elevation of IS and subsequent activation of the atrial NLRP3 inflammasome are key mechanisms in CKD-associated AF. Modulating the gut microbiota could provide a new therapeutic strategy for CKD-associated AF.
3. Semaglutide Reduces Murine Blood Pressure Through the Vascular Smooth Muscle GLP-1 Receptor.
Semaglutide lowers blood pressure in mice via GLP-1 receptors on vascular smooth muscle, not endothelial or immune cells, and requires VSMC GLP-1R for natriuresis and increased GFR. Ex vivo vasorelaxation and renal artery/kidney proteomic remodeling further implicate VSMC GLP-1R as the key cellular mediator.
Impact: Clarifies the cellular locus for GLP-1RA antihypertensive effects, decoupled from weight loss and endothelial signaling, with implications for optimizing cardio-renal benefits of GLP-1RAs.
Clinical Implications: Supports GLP-1RA use in hypertension/CV risk by identifying VSMC GLP-1R as a mediator of BP and natriuresis; informs development of agents/tissue targeting to maximize antihypertensive efficacy.
Key Findings
- VSMC GLP-1R is essential for semaglutide-induced blood pressure reduction; endothelial/immune GLP-1Rs are not required.
- VSMC GLP-1R is required for semaglutide’s increase in GFR and natriuresis but dispensable for effects on food intake, body weight, and glucose.
- Semaglutide induces ex vivo vasorelaxation and VSMC GLP-1R–dependent renal artery/kidney proteomic remodeling.
Methodological Strengths
- Cell type–specific genetic models distinguishing VSMC vs endothelial/immune GLP-1R roles.
- Convergent evidence from in vivo physiology, ex vivo vascular assays, and proteomics.
Limitations
- Findings derived from murine models; human translational validation is needed.
- Temporal dynamics and dose–response for chronic antihypertensive effects require further study.
Future Directions: Translate findings to humans via vascular imaging/biopsy or pharmacologic probes; explore tissue-targeted GLP-1R modulation to optimize antihypertensive and renal benefits.
GLP-1 receptor (GLP-1R) agonists decrease blood glucose and body weight and reduce rates of cardiovascular and renal disease. Although GLP-1R activation lowers blood pressure (BP), the underlying mechanisms remain incompletely understood and have been attributed to weight loss and endothelial cell GLP-1R signaling. Here, we show that GLP-1Rs in vascular smooth muscle cells (VSMCs) are essential for semaglutide-mediated BP reduction in mice. In contrast, GLP-1Rs in Tie2+ endothelial or immune cells are not required for semaglutide to lower BP. The VSMC GLP-1R is dispensable for the effects of semaglutide on food intake, body weight, and blood glucose, but is required for its actions to increase glomerular filtration rate and promote natriuresis. Systemic semaglutide administration resulted in proteomic changes in the renal artery and kidney in pathways related to platelet aggregation, fibrin clot formation, lipid metabolism, and pro-apoptotic signaling that are abolished in mice lacking VSMC GLP-1R expression. Moreover, semaglutide directly induced vasorelaxation in pre-constricted mesenteric arteries ex vivo. Together, these findings identify VSMCs as a key cellular target linking GLP-1R activation to BP regulation, renal electrolyte excretion, and proteomic changes in renal artery and kidney.